

# MODEL MANUSCRIPT

## Title Page

**TITLE: PAPER SHOULD BE WRITTEN IN CAMBRIA FONT ONLY (CAPITAL, CAMBRIA, 14 BOLD)**

**First Author Name<sup>†1</sup>, Second Author Name<sup>2</sup> (Cambria, 12 Bold)**

<sup>1</sup>(Department, Institute/Organization/University Name, Place-PIN Code, Country Name, E-mail ID) (Cambria, 10)

<sup>2</sup>(Department, Institute/Organization/University Name, Place-PIN Code, Country Name, E-mail ID) (Cambria, 10)

**†Corresponding Author:** Name, Department, Institute/ Organization/ University Name, Place-PIN Code, Country Name, Contact no., E-mail ID. (Cambria, 10)

### **1. ACKNOWLEDGEMENTS (CAMBRIA, CAPS, 12 BOLD)**

An acknowledgement section may be presented here, if any. (Cambria, 10)

### **2. DECLARATIONS (CAMBRIA, CAPS, 12 BOLD)**

Funding: Atgghha aaaaaaaaa aaaaaa (10)

Conflict of interest: Aaaaaa aaaaaaaaa aaaaaa (10)

Ethical approval: Aaaaaa aaaaaaaaa aaaaaa (10)

## Main Manuscript

**TITLE: PAPER SHOULD BE WRITTEN IN CAMBRIA  
FONT ONLY (CAPITAL, CAMBRIA, 14 BOLD)**

---

**Abstract (Cambria, 12 Bold) :** *The abstract should summarize the content of the paper. Try to keep the abstract below 300 words. Do not make references nor display equations in the abstract. The journal will be printed from the same-sized copy prepared by you. It is imperative that the margins and style described below be adhered to carefully. This will enable us to keep uniformity in the final printed copies of the Journal. Please keep in mind that the manuscript you prepare will be photographed and printed as it is received. Readability of copy is of paramount importance. (10 Italic)*

**Keywords: (10 Bold) -** *Write about Six Keywords or/and Key phrases, separated by comma (10 Italic)*

---

## 1. INTRODUCTION (CAMBRIA, CAPITAL, 12 BOLD)

The introduction of the paper should explain the nature of the problem, previous work, purpose, and the contribution of the paper. The contents of each section may be provided to understand easily about the paper. When you submit your paper print it in two-column format, including figures and tables [1]. In addition, designate one author as the “corresponding author”. This is the author to whom proofs of the paper will be sent. Proofs are sent to the corresponding author only [2]. (10)

## HEADINGS (CAMBRIA, CAPITAL, 12 BOLD)

The **headings [12 bold]** and **subheadings [10 bold]**, starting with "1. Introduction", appear in upper and lower case letters and should be **set in bold and aligned flush left**. All headings from the Introduction to Acknowledgements are numbered sequentially using 1, 2, 3, etc. Subheadings are numbered 1.1, 1.2, etc. If a subsection must be further divided, the numbers 1.1.1, 1.1.2, etc.

The font size for **heading is 12 points bold face** and **subsections with 10 points and bold**. Do not underline any of the headings, or add dashes, colons, etc. (10)


## INDENTATIONS AND EQUATIONS (10 BOLD)

The first paragraph under each heading or subheading should be flush left, and subsequent paragraphs should have a five-space indentation. A colon is inserted before an equation is presented, but there is no punctuation following the equation. All equations are numbered and referred to in the text solely by a number enclosed in a round bracket (i.e., (3) reads as "Eq. 3"). Ensure that any miscellaneous numbering system you use in your paper cannot be confused with a reference [4] or an equation (3) designation. (10, bold)

$$\text{(Eq. 3) Encapsulation efficiency} = \frac{\text{(Experimental content)}}{\text{(Theoretical content)}} \times 100$$

**FIGURES AND TABLES (10 Bold)**

To ensure a high-quality product, diagrams and lettering MUST be either computer-drafted or drawn using India ink.



**Figure 11: Contour plot and 3D response surface plot of SIF formulations showing the influence of amount of A (X<sub>1</sub>) & agitation speed (X<sub>3</sub>) on response Y<sub>3</sub> (10, bold).**

Figure captions appear below the figure, are flush left, and are in lower case letters. When referring to a figure in the body of the text, the abbreviation "Figure 1:" is used. Figures should be numbered in the order they appear in the text.

**Table 1: Compositions of EC microspheres formulations (10, bold)**

Sl. No.	Ingredients	Amount
1	A	0.9 g
2	B	0.45g
3	C	2g

Table captions appear centered above the table in upper and lower case letters. When referring to a table in the text, no abbreviation is used and "Table 1:" is capitalized. (10)

## 2. METHODS OR MATIRIALS & METHODS (CAMBRIA, CAPS, 12 BOLD)

Donotnnnreplicate (10)

## 3. RESULTS OR RESULTS & DISCUSSION (CAMBRIA, CAPS, 12 BOLD)

Donotnnnreplicate (10)

## 4. DISCUSSION (CAMBRIA, CAPS, 12 BOLD)

Donotnnnreplicate (10)

## 5. CONCLUSION (CAMBRIA, CAPS, 12 BOLD)

A conclusion section must be included and should indicate clearly the advantages, limitations, and possible applications of the paper. Although a conclusion may review the main points of the paper, do not replicate the abstract as the conclusion. A conclusion might elaborate on the importance of the work or suggest applications and extensions. (10)

## 6. REFERENCES (CAMBRIA, CAPS, 12 BOLD)

*This heading is not assigned a number.*

A reference list **MUST** be included using the following information as a guide. Only *cited* text references are included. Each reference is referred to in the text by a number enclosed in a square bracket (i.e., [3]). References **must be numbered and ordered according to where they are first mentioned in the paper**, NOT alphabetically.

Follow Harvard Reference Style:

<http://guides.is.uwa.edu.au/harvard>

[https://www.staffs.ac.uk/assets/harvard\\_quick\\_guide\\_tcm44-47797.pdf](https://www.staffs.ac.uk/assets/harvard_quick_guide_tcm44-47797.pdf)

Harvard Style Reference Generator: Reference Books, E-mails, Journals and Websites-

<http://www.neilstoolbox.com/bibliography-creator/>

**or**

**Examples follow:**

**Journal Papers:**

- [1] A. Garber, E. Klein, P. Mohideen, Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy. *Diabetes Obes Metab*, 2006, 8(2), 156-63. (10)
- [2] M. Ozaki, Y. Adachi, Y. Iwahori, and N. Ishii, Application of fuzzy theory to writer recognition of Chinese characters, *International Journal of Modelling and Simulation*, 1998, 18(2), 112-116. (10)

**Books:**

- [3] R.E. Moore, *Interval analysis* (Englewood Cliffs, NJ): Prentice-Hall, 1966). (10)

**Chapters in Books:**

- [4] P.O. Bishop, Neurophysiology of binocular vision, in J.Houseman (Ed.), *Handbook of physiology*, 4 (New York: Springer-Verlag, 1970) 342-366. (10)

**Thesis:**

- [5] D.S. Chan, Theory and implementation of multidimensional discrete systems for signal processing, doctoral diss., Massachusetts Institute of Technology, Cambridge, MA, 1978. (10)

**Proceedings Papers:**

- [6] W.J. Book, Modelling design and control of flexible manipulator arms: A tutorial review, *Proc. 29th IEEE Conf. on Decision and Control*, San Francisco, CA, 1990, 500-506 (10)
- [7] V.H.Tahiliani and J.W.Porter, "Fault Current Limiters - An Overview of EPRI Research", *IEEE Transactions on Power Apparatus and Systems*, Vol. PAS-99, no. 5, 1980, pp. 1964-1969.

## **Annexure**

### **Acknowledgement** (if any)

One or more statements should specify 1) contributions that need acknowledging but do not justify authorship, such as general support by a departmental chair; 2) acknowledgments of technical help; and 3) acknowledgments of financial and material support, which should specify the nature of the support. This should be included in the title page of the manuscript and not in the main article file.

### **Competing Interests**

All authors of must disclose any and all conflicts of interest they may have with publication of the manuscript or an institution or product that is mentioned in the manuscript and/or is important to the outcome of the study presented. Authors should also disclose conflict of interest with products that compete with those mentioned in their manuscript.

Or

The author(s) declares that he/she/they has/have no competing interests.

### **Funding**

Source(s) of support in the form of grants, equipment, drugs, or all of these.

Or

Sources of Funding: None

### **Registration number**

In case of a clinical trial and where it is registered (name of the registry and its URL)

### **Statement**

The manuscript has been read and approved by all the authors, that the requirements for authorship as stated earlier in this document have been met, and that each author believes that the manuscript represents honest work.